Clinical trial NCT01939353: Study of Flexible Doses of the Triple Reuptake Inhibitor EB-1020 Sustained Release (SR) in the Treatment of Adult Males With Attention-Deficit Hyperactivity Disorder
Official title: An Exploratory, Single-Blind Pilot Trial of Flexible Doses of the Triple Reuptake Inhibitor EB-1020 SR in the Treatment of Adult Males With Attention-Deficit Hyperactivity Disorder
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Adult ADHD
Keywords: Adult ADHD
centanafadine sustained release
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Sponsor class: INDUSTRY
First posted: 2013-09-11
Enrollment: 45
Sex: MALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This was a Phase 2 exploratory study to evaluate the efficacy and safety of EB-1020 SR (centanafadine sustained release \[CTN SR\]) in treating participants who met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) diagnostic criteria for Attention-Deficit Hyperactivity Disorder (ADHD) on the Mini International Neuropsychiatric Interview Plus, Version 6.0 (M.I.N.I.-Plus). Evaluations included determining an effectiveness signal for ADHD and related symptoms and exploring dosing, tolerability, onset of action, and duration of effect. Dose-response/tolerability relationships with CTN SR were also explored. The 1-week placebo run-in \[single-blind (SB)\] was also used for informal safety comparison purposes.

Detailed description: This Phase 2, flexible-dosage, single-blind exploratory study of CTN SR in adult male participants with ADHD consisted of a 1-week placebo run-in (SB), 4 weeks of treatment with CTN SR, and 2 weeks of follow-up. At the placebo run-in, participants must have had a score of greater than or equal to 28 on the Adult Attention-Deficit Hyperactivity Disorder Rating Scale Version IV (ADHD-RS-IV) to be eligible to continue participation in the study.

At the end of single-blind placebo run-in treatment (that is, beginning of CTN SR treatment), the ADHD-RS-IV with adult prompts was re-administered. Participants who showed an improvement greater than or equal to 30% over baseline values or who had a score of less than 28 on the ADHD-RS-IV were withdrawn from the study prior to receiving any active drug. Those who showed less than 30% improvement from the placebo run-in to the beginning of CTN SR treatment continued the study. The consent form was phrased such that participants were not informed of the exact timing of CTN SR versus placebo treatment in order to maintain the blinded nature of the placebo treatment and reduce potential placebo effects. Dosing was flexible, with a target maximum dosage of 500 milligrams (mg) daily in divided doses (morning and afternoon, approximately 5 hours later) to be achieved if possible during Week 2 of CTN SR treatment. The participants took a starting dose of 100 mg of CTN SR daily; the dose was titrated in 100 mg increments up to the maximum dosage of 500 mg daily. The treating physician escalated the dose to the maximum dose if participants had not achieved remission of ADHD in his/her judgment, and CTN SR was still well tolerated. If in the physician's judgment the participant could not tolerate further dose escalation, or was not tolerating the current dose well, the dose was maintained or reduced, with the goal of re-assessing dose and response at the subsequent visit for a possible increase in dose, until study completion.

Eligibility criteria: Inclusion Criteria:

1. Participants had to be able to understand the nature of the study, agree to comply with the prescribed dosage regimens, report for regularly scheduled office visits, and communicate to study personnel about adverse events and concomitant medication use.
2. Participants must have met DSM-IV-TR diagnostic criteria for ADHD (Combined, Predominantly Inattentive or Predominantly Hyperactive-Impulsive Types) on the M.I.N.I.-Plus.
3. Participants must have had an ADHD-RS-IV score of greater than or equal to 28 at the placebo run-in baseline and CTN SR treatment baseline.
4. Participants must have had a Clinical Global Impression of Severity (ADHD version) score of greater than or equal to 4.
5. Participants must be able to read well enough to understand the informed consent form and other participant materials.
6. Participants must have been able to be reliably rated on the psychiatric scales required by the protocol based on investigator's judgment.
7. Participants must have been able to read and understand English.
8. Participants must have had a body mass index of approximately 18 to 35 kilograms/meter squared.
9. Sexually active, fertile males must have used effective birth control if their partners were women of childbearing potential. Women of childbearing potential (if a partner of a male participant) included any female who had experienced menarche and who had not undergone successful surgical sterilization or women on hormone replacement therapy with documented serum follicle stimulating hormone level greater than 35 milli-international units/milliliter. Even women who were using oral contraceptives, other hormonal contraceptives (vaginal products, skin patches, or implanted or injectable products), or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy, or were practicing abstinence or where the partner was sterile (for example, vasectomy), should have been considered to be of childbearing potential.

Exclusion Criteria:

1. Participant had a DSM-IV-TR diagnosis of ADHD not otherwise specified.
2. Participants rated as having a greater than or equal to 30% improvement in ADHD symptoms or a score of less than 28 on the ADHD-RS-IV after Week 1 (placebo run-in). Such participants were withdrawn from the study prior to receiving any active drug.
3. Participant had a current or lifetime history of bipolar disorder or any psychotic disorder as established by M.I.N.I.-Plus.
4. Participant had a current history (past 90 days) of major depression, generalized anxiety disorder, obsessive-compulsive disorder, panic disorder or post-traumatic stress disorder as established by the M.I.N.I.-Plus.
5. History in the past 20 years of electroconvulsive therapy or lifetime history of vagal nerve stimulation or deep brain stimulation for the treatment of depression.
6. Participants with a history of drug or alcohol use disorders (abuse or dependence) must have been free of the diagnosis and of substance use for at least 6 months prior to the Screening visit.
7. Participant had a history of epilepsy, seizures, syncope, unexplained blackout spell(s), head trauma with clinically significant loss of consciousness or noninfantile febrile seizures.
8. Participant had a currently active medical condition (other than ADHD) that, in the opinion of the investigator, could have interfered with the ability of the participant to participate in the study safely.
9. Participant had a history of clinically significant, diagnosed cardiovascular disease of any kind, including uncontrolled hypertension. Participant had newly diagnosed cardiovascular disease of any kind in the investigator's judgment.
10. The participant had an intelligence quotient less than 80.
11. In the opinion of the investigator, the participant had not derived significant therapeutic benefit from 2 or more ADHD therapies given with an adequate dose and duration in adulthood (age 18 or older); that is, 1 failed course of treatment was acceptable, but 2 failed courses of treatment were not acceptable.
12. Participant taking medication specifically for treatment of ADHD symptoms (for example, stimulants, atomoxetine, tricyclic antidepressants, bupropion, modafinil) must have been off stimulants for 2 weeks and off nonstimulant ADHD therapies for 3 weeks prior to the placebo run-in visit and must have returned to the baseline level of ADHD symptoms in the opinion of the investigator. Participants must not have had evidence of a discontinuation or withdrawal reaction.
13. Participant was currently taking any antidepressant medication for any condition.
14. Participant was currently taking antipsychotic medication or an anticonvulsant medication (for example, phenytoin, carbamazepine, lamotrigine, or valproic acid) at anticonvulsant doses.
15. Participant had a known history of allergy to CTN.
16. Participant was unwilling to refrain from taking medications that may have interfered with the assessment of cognitive function and the assessment of sleep. Examples included benzodiazepines, sedating antihistamines, zolpidem, eszopiclone, and zaleplon. Herbal preparations with effects on the central nervous system also were prohibited throughout the study (for example, St. John's Wort or melatonin).
17. Participant had a history of sleep problems in the last 3 months.
18. Participant was unwilling to refrain from taking more than 1 unit of alcohol within 24 hours of the investigational center visits.
19. Participant was unwilling to restrict caffeine to no more than 500 mg/day (5 cups of coffee).
20. Participant was actively using any drugs with potential for abuse (for example, marijuana, cocaine, amphetamines).
21. Participant reported passive or active suicidal ideation or intent.
22. Participant was concurrently participating in another clinical research study or investigational drug study or had participated in such a study within the past 1 month.
23. Participant was at high risk of nonadherence to investigational product and the protocol regimen in the investigator's opinion.
24. Participant could not have begun psychotherapy during the study, but may have continued therapy at the same intensity and frequency, if begun at least 3 months prior to placebo run-in.

Exclusion Criteria, Physical and Laboratory Test Findings

1. Participants who had a positive urine drug screen, which could not be explained by prescribed medications. The urine drug screen may have been repeated based on investigator judgment.
2. Participants with clinically significantly abnormal thyroid-stimulating hormone or a positive result on a standard hepatitis-screening panel or human immunodeficiency virus screen. Note: Adequate thyroid replacement for a previously diagnosed thyroid deficiency, which had been stable for 3 months or more, was acceptable.
3. Participants with clinically significant laboratory abnormalities or with clinical laboratory values of potential clinical concern.
4. Diastolic blood pressure greater than 85 millimeters of mercury (mmHg) at placebo run-in.
5. Systolic blood pressure greater than 135 mmHg at placebo run-in.
6. Participant had a QT interval of greater than 450 milliseconds on 2 or more electrocardiogram tracings taken within 15 minutes, assessed with the participant in a supine position for 3 minutes.

Other Exclusion Criteria

1. Prisoners or participants who were involuntarily incarcerated.
2. Participants who had a compulsory detainment for treatment of either a psychiatric or a physical illness.
3. Participants who planned to have elective surgeries during the course of the study.
4. Participants with a history of antidepressant-induced hypomania or dysphoria.

Primary outcomes:
measure: Change From Baseline-2 in ADHD Symptoms to Week 4 as Assessed by the Adult Attention-Deficit Hyperactivity Disorder Rating Scale (AD HD-RS-IV)
timeFrame: Baseline, Week 4
Secondary outcomes:
measure: Change From Baseline-2 in ADHD Symptoms as Assessed by the Adult ADHD-RS-IV
timeFrame: Baseline-2, Weeks 1, 2, 3, and 6 (Follow-up Visit)
measure: Change From Baseline-2 to Week 4 on the Behavior Rating Inventory of Executive Function, Adult Version (BRIEF-A) Scale
timeFrame: Baseline-2 and Week 4
measure: Percentage of Participants Who Are Responders for ADHD Symptoms as Measured by the ADHD-RS-IV
timeFrame: Baseline-2, Weeks 1, 2, 3, and 4
measure: Percentage of Participants Who Are High Responders for ADHD Symptoms as Measured by the ADHD-RS-IV
timeFrame: Baseline-2, Weeks 1, 2, 3, and 4
measure: Change From Baseline-2 on the Inattentiveness and Hyperactivity/Impulsivity Subscales of ADHD-RS-IV
timeFrame: Baseline-2, Weeks 1, 2, 3 and 4
measure: Change From Baseline-2 in the Clinical Global Impression of Severity (CGI-S) [ADHD Version] Scale Score
timeFrame: Baseline-2, Weeks 1, 2, 3, 4 and 6 (Follow-up Visit)
measure: Change From Baseline-2 in the Clinical Global Impression of Improvement (CGl-I) [ADHD Version] Scale Score
timeFrame: Baseline-2, Weeks 1, 2, 3, 4 and 6 (Follow-up)
measure: Percentage of Responders to the CGl-I (ADHD Version) Scale
timeFrame: Weeks 4 and 6 (Follow-up Visit)
measure: Change From Baseline-2 in the Columbia-Suicide Severity Rating Scale (C-SSRS)
timeFrame: Baseline-2, Weeks 1, 4, and 6 (Follow-up Visit)
measure: Change From Baseline-2 on the Profile of Mood States, Second Edition, Short Version 2A (POMS 2-A Short) at Week 4
timeFrame: Baseline-2 and Week 4
measure: Change From Baseline-2 on the Wender-Reimherr Adult Attention Deficit Disorder Scale (WRAADDS) at Week 4
timeFrame: Baseline-2 and Week 4
measure: Change From Baseline-2 on the Weiss Functional Impairment Rating Scale - Self Report (WFIRS-S) at Week 4
timeFrame: Baseline and Week 4
measure: Change From Week 4 to End of Discontinuation Phase (Follow-up) on the ADHD-RS-IV
timeFrame: Week 4 and end of Discontinuation Phase (Week 6)
Other outcomes:
Locations:
city: Bradenton
country: United States
state: Florida
city: Maitland
country: United States
state: Florida
city: Las Vegas
country: United States
state: Nevada
Study officials:
References: